Lofepramine | CAS# 23047-25-8 | Antidepressant

MedKoo Cat#: 581252 | Name: Lofepramine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lofepramine is a first generation tricyclic antidepressant. Lofepramine is a serotonin and noradrenaline re-uptake inhibitor (SNRI) that is metabolized to desipramine (sc-200158, sc-207535). Lofepramine produces inhibition of liver tryptophan pyrollase activity in vitro.

Chemical Structure

Lofepramine

CAS#23047-25-8

Theoretical Analysis

MedKoo Cat#: 581252

Name: Lofepramine

CAS#: 23047-25-8

Chemical Formula: C26H27ClN2O

Exact Mass: 418.1812

Molecular Weight: 418.97

Elemental Analysis: C, 74.54; H, 6.50; Cl, 8.46; N, 6.69; O, 3.82

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,450.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 5,650.00	2 Weeks
5g	USD 7,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

26786-32-3(HCl) 23047-25-8

Synonym

Lofepramine; HSDB 7184; Amplit; LEO 640; Lofepraminum; Lopramine;

IUPAC/Chemical Name

4'-Chlor-2-((3-(10,11-dihydro-5H-dibenz(b,f)azepin-5-yl)propyl)methylamino)acetophenon

InChi Key

SAPNXPWPAUFAJU-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3

SMILES Code

O=C(C1=CC=C(Cl)C=C1)CN(CCCN2C3=CC=CC=C3CCC4=CC=CC=C42)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Lofepramine (Lopramine) is a potent tricyclic antidepressant and is extensively metabolised to Desipramine.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	23.87
	DMF:PBS (pH 7.2) (1:3)	0.3	0.60
	DMSO	28.1	97.17
	Ethanol	4.2	10.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 418.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Feighner JP, Meridith CH, Dutt JE, Hendrickson GG. A double blind comparison of lofepramine, imipramine and placebo in patients with depression. Acta Psychiatr Scand. 1982 Aug;66(2):100-8. PubMed PMID: 6753500. 2: Lancaster SG, Gonzalez JP. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1989 Feb;37(2):123-40. Review. PubMed PMID: 2649353. 3: Herdman JR, Cowen PJ, Campling GM, Hockney RA, Laver D, Sharpley AL. Effect of lofepramine on 5-HT function and sleep. J Affect Disord. 1993 Sep;29(1):63-72. PubMed PMID: 8254146. 4: Leonard BE. A comparison of the pharmacological properties of the novel tricyclic antidepressant lofepramine with its major metabolite, desipramine: a review. Int Clin Psychopharmacol. 1987 Oct;2(4):281-97. Review. PubMed PMID: 2891742. 5: Ghose K, Spragg BP. Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects. Int Clin Psychopharmacol. 1989 Jul;4(3):201-15. PubMed PMID: 2677125. 6: Hopes H. Effects of lofepramine on human sleep: a pilot study. Int Clin Psychopharmacol. 1989 Oct;4(4):295-300. PubMed PMID: 2607127. 7: Strandgården K, Gunnarsson PO. Metabolism of lofepramine and imipramine in liver microsomes from rat and man. Xenobiotica. 1994 Aug;24(8):703-11. PubMed PMID: 7839694. 8: Tan RS, Barlow RJ, Abel C, Reddy S, Palmer AJ, Fletcher AE, Nicholl CG, Pitt BM, Bulpitt CJ. The effect of low dose lofepramine in depressed elderly patients in general medical wards. Br J Clin Pharmacol. 1994 Apr;37(4):321-4. PubMed PMID: 8018452; PubMed Central PMCID: PMC1364731. 9: Marneros A, Philipp M. A double-blind trial with amitriptyline and lofepramine in the treatment of endogenous depression. Int Pharmacopsychiatry. 1979;14(5):300-4. PubMed PMID: 395129. 10: Elm T, Hansen EL. Simultaneous determination of lofepramine and desipramine by a high-performance liquid chromatographic method used for therapeutic drug monitoring. J Chromatogr B Biomed Appl. 1995 Mar 24;665(2):355-61. PubMed PMID: 7795815. 11: Darcy P, Kelly JP, Leonard BE, Henry JA. The effect of lofepramine and other related agents on the motility of Tetrahymena pyriformis. Toxicol Lett. 2002 Mar 10;128(1-3):207-14. PubMed PMID: 11869831. 12: Ghose K, Sedman E. A double-blind comparison of the pharmacodynamic effects of single doses of lofepramine, amitriptyline and placebo in elderly subjects. Eur J Clin Pharmacol. 1987;33(5):505-9. PubMed PMID: 3428344. 13: Puri BK, Bydder GM, Chaudhuri KR, Al Saffar BY, Curati WL, White SJ, Mitchell L, Hajnal JV, Horrobin DF. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport. 2001 Jul 3;12(9):1821-4. PubMed PMID: 11435905. 14: Reid F, Henry JA. Lofepramine overdosage. Pharmacopsychiatry. 1990 Jan;23 Suppl 1:23-7. Review. PubMed PMID: 2408087. 15: Kelly JP, Leonard BE. An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized rat models of depression. Eur Neuropsychopharmacol. 1999 Jan;9(1-2):101-5. PubMed PMID: 10082234. 16: Kerihuel JC, Dreyfus JF. Meta-analyses of the efficacy and tolerability of the tricyclic antidepressant lofepramine. J Int Med Res. 1991 May-Jun;19(3):183-201. PubMed PMID: 1834491. 17: Kelly C, Roche S, Naguib M, Webb S, Roberts M, Pitt B. A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int Clin Psychopharmacol. 1993 Summer;8(2):83-6. PubMed PMID: 8102151. 18: Lofepramine: a return to tricyclic antidepressives. Drug Ther Bull. 1983 Dec 16;21(25):99-100. PubMed PMID: 6662044. 19: Pugh R, Bell J, Cooper AJ, Dunstan S, Greedharry D, Pomeroy J, Raptopoulos P, Rowsell C, Steinert J, Priest RG. Does lofepramine have fewer side effects than amitriptyline? Results of a comparative trial. J Affect Disord. 1982 Dec;4(4):355-63. PubMed PMID: 6219149. 20: Pitt BM. Lofepramine in the elderly. Int Clin Psychopharmacol. 1988 Nov;3 Suppl 2:49-54. Review. PubMed PMID: 3063744.